{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:05:31Z","timestamp":1779919531909,"version":"3.53.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Case-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107\u2013147.5) vs. 94.5 (80\u2013127.5) mg\/dl, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were significantly higher, levels of HDL (56\u2009\u00b1\u200916.7 vs. 69.2\u2009\u00b1\u200914.6\u2009mg\/dl, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.<\/jats:p>\n                <jats:p>After a median of 10\u2009weeks (IQR 7\u201318\u2009weeks) after initiation of cabergoline, total (from 212.5\u2009\u00b1\u200936.2 to 196.9\u2009\u00b1\u200940.6\u2009mg\/dl, <jats:italic>p<\/jats:italic>\u2009=\u20090.018) and LDL cholesterol (130 (107\u2013147.5) to 106.5 (94.3\u2013148) mg\/dl, <jats:italic>p\u2009=<\/jats:italic>\u00a00.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00733-6","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T10:06:17Z","timestamp":1619431577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study"],"prefix":"10.1186","volume":"21","author":[{"given":"Anna Sophia","family":"Posawetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Pandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Pieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Theiler-Schwetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"11","key":"733_CR1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/BF03345636","volume":"31","author":"EC Naliato","year":"2008","unstructured":"Naliato EC, Violante AH, Gaccione M, Caldas D, Lamounier Filho A, Loureiro CR, et al. Body fat in men with prolactinoma. J Endocrinol Investig. 2008;31(11):985\u201390.","journal-title":"J Endocrinol Investig"},{"key":"733_CR2","doi-asserted-by":"crossref","unstructured":"Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013;79(6):845\u201352.","DOI":"10.1111\/cen.12204"},{"issue":"4","key":"733_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1463-1326.2006.00671.x","volume":"9","author":"T Brandebourg","year":"2007","unstructured":"Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007;9(4):464\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"733_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1046\/j.1365-2826.2003.01092.x","volume":"15","author":"AD Strader","year":"2003","unstructured":"Strader AD, Buntin JD. Changes in agouti-related peptide during the ring dove breeding cycle in relation to prolactin and parental hyperphagia. J Neuroendocrinol. 2003;15(11):1046\u201353.","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"733_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000054522","volume":"71","author":"KG Bina","year":"2000","unstructured":"Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in Ob\/Ob mice. Neuroendocrinology. 2000;71(1):68\u201378.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"733_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1365-2265.2007.02973.x","volume":"67","author":"EC Naliato","year":"2007","unstructured":"Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol. 2007;67(6):845\u201352.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"733_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM dos Santos Silva","year":"2011","unstructured":"dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19(4):800\u20135.","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"733_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1055\/s-0032-1321832","volume":"44","author":"LF de Assuncao Alves Rodrigues","year":"2012","unstructured":"de Assuncao Alves Rodrigues LF, Campos SM, Miranda PA, Bizzi MF, Sales do Amaral PH, Giannetti AV, et al. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012;44(11):832\u20138.","journal-title":"Horm Metab Res"},{"issue":"27","key":"733_CR9","first-page":"1705","volume":"3","author":"J Tourniaire","year":"1974","unstructured":"Tourniaire J, Pallo D, Pousset G, Bizollon C, Bachelot I. Diminished glucose tolerance and hyperinsulinism due to prolactin secreting adenoma. Nouv Press Med. 1974;3(27):1705\u20137.","journal-title":"Nouv Press Med"},{"issue":"4","key":"733_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Granieri L, Galdiero M, Simeoli C, Perone Y, Vitale P, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98(4):299\u2013310.","journal-title":"Neuroendocrinology"},{"key":"733_CR11","doi-asserted-by":"crossref","unstructured":"Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. 2013;44(1):193\u20139.","DOI":"10.1007\/s12020-012-9857-y"},{"issue":"1","key":"733_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11011-016-9882-2","volume":"32","author":"V Schwetz","year":"2017","unstructured":"Schwetz V, Librizzi R, Trummer C, Theiler G, Stiegler C, Pieber TR, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017;32(1):155\u201361.","journal-title":"Metab Brain Dis"},{"issue":"2","key":"733_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"733_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0031-9384(98)00288-1","volume":"66","author":"JD Buntin","year":"1999","unstructured":"Buntin JD, Hnasko RM, Zuzick PH. Role of the ventromedial hypothalamus in prolactin-induced hyperphagia in ring doves. Physiol Behav. 1999;66(2):255\u201361.","journal-title":"Physiol Behav"},{"issue":"1","key":"733_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0006-8993(96)00227-2","volume":"729","author":"D Sauve","year":"1996","unstructured":"Sauve D, Woodside B. The effect of central administration of prolactin on food intake in virgin female rats is dose-dependent, occurs in the absence of ovarian hormones and the latency to onset varies with feeding regimen. Brain Res. 1996;729(1):75\u201381.","journal-title":"Brain Res"},{"issue":"1","key":"733_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147(1):77\u201384.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"733_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","volume":"48","author":"Y Greenman","year":"1998","unstructured":"Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol. 1998;48(5):547\u201353.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"733_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148(3):325\u201331.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"733_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1210\/endo.142.2.7979","volume":"142","author":"M Freemark","year":"2001","unstructured":"Freemark M, Fleenor D, Driscoll P, Binart N, Kelly P. Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology. 2001;142(2):532\u20137.","journal-title":"Endocrinology"},{"issue":"4","key":"733_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1210\/jc.2002-021137","volume":"88","author":"C Ling","year":"2003","unstructured":"Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88(4):1804\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"733_CR21","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"733_CR22","first-page":"3469","volume":"81","author":"IG Brodsky","year":"1996","unstructured":"Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3469\u201375.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"733_CR23","first-page":"2647","volume":"84","author":"PJ Snyder","year":"1999","unstructured":"Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647\u201353.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"733_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","volume":"101","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66\u201381.","journal-title":"Neuroendocrinology"},{"key":"733_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fendo.2019.00327","volume":"10","author":"RS Auriemma","year":"2019","unstructured":"Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front Endocrinol (Lausanne). 2019;10:327.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"18","key":"733_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/eurheartj\/ehs233","volume":"35","author":"R Haring","year":"2014","unstructured":"Haring R, Friedrich N, Volzke H, Vasan RS, Felix SB, Dorr M, et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J. 2014;35(18):1215\u201321.","journal-title":"Eur Heart J"},{"issue":"2","key":"733_CR27","doi-asserted-by":"publisher","first-page":"10.1161\/JAHA.11","DOI":"10.1161\/JAHA.115.002640","volume":"5","author":"KE Therkelsen","year":"2016","unstructured":"Therkelsen KE, Abraham TM, Pedley A, Massaro JM, Sutherland P, Hoffmann U, et al. Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study. J Am Heart Assoc. 2016;5(2):10.1161\/JAHA.115.002640.","journal-title":"J Am Heart Assoc"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00733-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T10:14:18Z","timestamp":1619432058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00733-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00733-6","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"16 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. The Ethics Committee of the Medical University of Graz approved this study (26\u2013533 ex 13\/14). All participants gave their written informed consent before any study-related procedures were carried out.All methods were carried out in accordance with current guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}